There is increasing public awareness that repetitive concussions or mild traumatic brain injury (TBI) can cause long-term symptoms, known as postconcussive syndrome (PCS); moreover, even mild brain injuries, when repeated, can sometimes lead to chronic, progressive neurodegeneration known as chronic traumatic encephalopathy (CTE). The risk of long-term and chronic conditions related to repetitive mild TBI is of substantial public health relevance, as large groups of young people expose themselves to an elevated risk of repetitive mild TBI in certain sports, in military service, and in certain occupations.
There is increasing public awareness that repetitive concussions or mild traumatic brain injury (TBI) can cause long-term symptoms, known as postconcussive syndrome (PCS); moreover, even mild brain injuries, when repeated, can sometimes lead to chronic, progressive neurodegeneration known as chronic traumatic encephalopathy (CTE). The risk of long-term and chronic conditions related to repetitive mild TBI is of substantial public health relevance, as large groups of young people expose themselves to an elevated risk of repetitive mild TBI in certain sports, in military service, and in certain occupations.
We need biomarkers for mild TBI and related conditions to better understand the relationship between repetitive mild TBI and chronic neurological symptoms, identify individuals at particularly high risk of long-term sequelae of mild TBI, and develop strategies to prevent development of chronic disease after mild TBI.
This Review focuses on the considerable progress that has been made in the search for fluid bio markers for mild TBI in recent years, with an emphasis on markers for neuronal, axonal, oligodendrocytic, astroglial and blood-brain barrier injury in the context of mild TBI. We also discuss developments with regard to biomarkers for PCS and CTE. Moreover, we review biomarkers for neuroinflammation and metabolic dysregulation in these disorders. We also discuss technical and standardization issues and potential pathways to move the most promising biomarker candidates forward into clinical laboratory practice.
TBI and related conditions TBI is caused by the impact of an external mechanical force on the brain. In moderate to severe TBI, intracranial bleeding and/or mass lesions are present in the brain parenchyma, and the condition is diagnosed by clinical examination and standard neuroimaging techniques, such as CT or MRI of the brain 1 . Clinically, TBI can be graded using the Glasgow Coma Scale, in which the patient's conscious state is rated on the basis of eye, verbal and motor responses to different stimuli 2 . However, the prognostic utility of this and similar scales is under debate, and additional subclassification with novel biomarkers remains an unmet clinical need, as extensively discussed elsewhere 3 .
Mild TBI
Diagnosis of mild TBI: a clinical conundrum. Mild TBI -a term that is often used interchangeably with concussion -is defined as head trauma resulting in brief loss of consciousness and/or alteration of mental state (BOX 1) , which is difficult to diagnose objectively. Currently, mild TBI is a clinical diagnosis based on self-reported symptoms after blunt head injury, and A recently discovered 'waste clearance' pathway from the vertebrate CNS into the bloodstream. Clearance of compounds that accumulate after mild traumatic brain injury through this pathway could influence blood biomarker concentrations.
presents an everyday challenge in emergency care units around the world. The development of strategies to objectively diagnose TBI should not be neglected, for several reasons. First, studies have indicated that 7-20% of patients presenting to the emergency room with suspected concussion show an intracranial abnormality (contusion or haemorrhage) on a day-of-injury CT scan 4 . Second, around 15% of patients with mild TBI develop incapacitating symptoms for >10 days following the injury; these longer-term symptoms are often termed postconcussive syndrome (PCS) 5 . Last, reports linking CTE with repetitive mild TBI suggest that care should be taken to minimize the risk of a new concussion before proper recovery has been secured 5 .
Mechanisms of injury.
Concussion per se causes no gross pathology, such as haemorrhage, and no abnormalities are seen on conventional CT scans of the brain 6 . Rather, mild TBI is a rapid-onset neuronal dysfunction that often resolves in a spontaneous manner over a few days to weeks. The main cause of the symptoms in mild TBI is thought to be axonal injury caused by acceleration or deceleration and/or rotational forces on the brain parenchyma, which result in rapid stretching of axons 5 . Neuroinflammation and/or microglial activation can also be involved. Novel MRI techniques, such as diffusion tensor imaging (DTI), can be used to monitor axonal integrity, but conclusive evidence of their sensitivity to detect axonal injury in mild TBI is lacking 7, 8 .
Postconcussive syndrome
Approximately 15% of patients with concussion show cognitive or neurological dysfunction that continues for months or more after the initial injury 9, 10 , and such patients can fulfil the criteria for PCS 11 . PCS has been the subject of intense debate, because the diagnosis is associated with a wide range of nonspecific physical symptoms, such as headache and cognitive complaints -for example, difficulty concentrating -and emotional and/or behavioural symptoms, such as irritability. Also, the risk of PCS is influenced not only by injury mechanisms but also by psychological and socioeconomic factors 12 . Why PCS develops in some patients with concussion and not in others is unknown [12] [13] [14] .
Chronic traumatic encephalopathy
Repetitive concussions are thought to be a risk factor for CTE, a neuropathological diagnosis that was first described in boxers 15 , but has also recently been observed in other sports athletes and in military veterans 16 . Clinically, the condition is characterized by chronic and sometimes progressive neurological and/or psychiatric symptoms 16 . The molecular pathology of CTE is characterized by tau-positive neurofibrillary tangles and neuropil threads that can be present in any region of the brain 16 . Neurofibrillary tangles in CTE are most often formed in the superficial cortical layers, rather than in deeper layers as is more common in Alzheimer disease (AD); moreover, focal tau accumulations develop in the depths of the sulci 17 . Another -perhaps the most distinctive -feature of CTE is perivascular tau deposition, which could reflect an association of tau deposition with TBIrelated injury to cerebrovascular endothelial cells, which may promote tau deposition through mechanisms that are as yet unclear 17 . The relationship between PCS and future development of CTE is unknown. Potentially, a fraction of patients with PCS will eventually be diagnosed with CTE; however, given the current lack of biomarkers to help diagnose CTE in living humans, the size of this fraction is currently unknown.
The potential of fluid biomarkers in TBI A fluid biomarker is defined as a molecule that is measurable (that is, its concentration or activity can be quantified) in a biological fluid, and the measure must relate to a physiological or pathological process that occurs in a living cell or organism. In TBI research and clinical work-up, fluid biomarkers have the potential to help to define TBI severity (including the severity of different types of injury, such as axonal injury and microvascular damage), adaptive and recovery processes following TBI, the transition between a normal injury-recovery pattern and a progressive CTE process, and treatment response in clinical trials. For most of the biomarker candidates discussed in this Review, these potential contexts of use have not yet been tested in appropriate clinical settings.
Sample types for fluid biomarkers

Cerebrospinal fluid
Cerebrospinal fluid (CSF) provides mechanical support and protection for the brain, and has an important role in the transport of molecules to and from neurons. Metabolites are cleared from neurons to the CSF, and from the CSF into the blood via arachnoid villi 18 , as well as through meningeal lymphatic vessels 19 . The recent discovery of the so-called glymphatic system has helped to explain how subarachnoid CSF can enter and exit the brain along paravascular spaces and clear the brain parenchyma of extracellular metabolites and other breakdown products 20 . In adults, the total CSF volume is around 150 ml, and the fluid is produced and cleared at a rate of around 20 ml per hour 18 .
Key points
• Traumatic brain injury (TBI) is caused by an external mechanical force that injures the brain parenchyma; however, most patients with mild TBI show no signs of injury on a CT scan • Given that mild TBI cannot usually be diagnosed objectively, accurate fluid biomarkers would be a welcome addition to the diagnostic toolbox • Repetitive mild TBI can cause progressive neurodegeneration, known as chronic traumatic encephalopathy (CTE); however, estimating the risk of CTE is difficult, and the condition cannot be diagnosed in living patients • In future, biomarkers for mild TBI, postconcussive syndrome and CTE might help us predict the risk of long-term sequelae and improve our understanding of the underlying pathophysiology • Brain specificity or brain-enhanced expression is an important characteristic of blood-based biomarkers for mild TBI and related conditions, as extracerebral sources for biomarker molecules can compromise the interpretability of the test results • In mild TBI, fluid biomarkers for axonal injury and astroglial activation show the greatest promise at the moment, and several other promising biomarker candidates exist
Sampling. CSF sampling via lumbar puncture can be performed in the outpatient setting, and standard operating practices have been established 21 . Lumbar puncture is safe; the only notable adverse effect is transient headache following the procedure, which affects 2-20% of patients 22 . In severe TBI, CSF can be sampled through intraventricular or extraventricular catheters, but it is important to take into account that intracranial CSF differs in protein composition from lumbar CSF, so biomarker concentrations from the two fluid types cannot be directly compared 23 .
Advantages and disadvantages.
The main advantage of CSF as a matrix in which to measure markers of CNS injury is that it communicates freely with the brain interstitial fluid that bathes the neurons. Thus, biochemical changes in the brain are often reflected in the CSF, which can be regarded as an accessible, though not perfect, sample of the brain interstitial fluid. Furthermore, CSF has low protease activity, and most molecules do not change on sampling provided that the sample is not contaminated by blood. The main disadvantage is that lumbar puncture can be regarded as invasive. Finally, although CSF allows sampling from the brain side of the blood-brain barrier, it should be remembered that only 20-30% of the CSF volume is derived from the brain; 70-80% is a filtrate of plasma, produced by the choroid plexus 18 .
Blood
The other major biofluid for TBI biomarker analysis is blood (serum or plasma), which communicates with the brain and CSF compartments through the glymphatic system 20 . Measurement of CNS-related biomarkers in the blood is hampered by several biological and technical issues. First, a biomarker that originates in the CNS has to cross the blood-brain barrier in order to be detected in the periphery and, if the concentration of the biomarker molecule in the CSF is low, it will be even lower in the blood, given that the blood:CSF volume ratio causes a substantial dilution. Second, if the biomarker is not specific for the CNS but is also expressed in peripheral tissues that can be injured in trauma, the contribution from the CNS will potentially be drowned out in the high biological background caused by non-CNS sources. A good tool to assess the risk of this 'contamination' is the publicly available web-based Human Protein Atlas, which presents mRNA and protein expression data for almost 20,000 proteins in 44 different human tissues 24 . Third, the huge quantities of other proteins (such as albumin and immunoglobulins) in the blood introduces analyti cal challenges due to possible interference 25 . Fourth, heterophilic antibodies can be present in blood, and can interfere in immunoassays (see below for more details) 26 . Fifth, the analyte of interest can undergo proteolytic degradation by various proteases in plasma 27 . Sixth, clearance of the biomarker by the liver or the kidneys can introduce interindividual variability. Last, recent data, derived from a mouse model of TBI, suggest that sleep deprivation and cisternotomy can inhibit glymphatic clearance and thereby suppress TBIinduced increases in serum biomarker levels 28 . Whether these potential confounders are relevant also in humans remains to be examined.
Saliva, urine and tears
It is possible that some CNS-derived proteins are eventually excreted into body fluids other than CSF and blood. The presence of the CNS-enriched protein tau in saliva has been demonstrated using mass spectrometry 29 , and the same research group detected α-synuclein and DJ-1 (molecules related to cerebral pathologies in Parkinson disease) in saliva 30 . However, the relationship between salivary concentrations of these proteins and processes within the CNS is far from clear, and no conclusive data on disease association have been reported so far.
At present, it is hard to imagine how a test based on sampling of saliva, urine or tears could produce results with a clear link to changes in the brain, given the many barriers and compartments that the marker has to cross on its way to the sampling site. Furthermore, expression of, for example, tau mRNA and protein in both salivary glands and kidney (tau data in the Human Protein Atlas) could further limit the interpretability of measurements in these fluids. In our opinion, these fluids are unlikely to yield useful markers in the foreseeable future, so they will not be discussed further here.
Measurement techniques ELISA
Most biomarker assays of relevance to TBI are immunochemical; that is, they use antibodies to quantify a substance in a sample. The most common assay format is the 'sandwich' ELISA, in which the target analyte is captured in a complex between two antibodies, one of which carries a signal generator -an enzyme that converts a substrate into a detectable form (coloured, fluorescent or luminescent). Comparison of the generated 
Wallerian degeneration
When a nerve fibre is injured, the part of the axon separated from the neuron's cell body degenerates distal to the injury -this phenomenon is termed Wallerian degeneration.
signal with a calibrator curve (derived from artificial samples with known analyte concentrations) enables quantification of the analyte of interest. ELISA is a theme with many variations; for example, the signal generator enzyme can be replaced by a fluorophore or a DNA-based detection system. Multiplex ELISA. Immunochemical assays can also be multiplexed in different ELISA-like formats, thereby enabling simultaneous measurement, in the same sample, of markers that reflect distinct and unique axes of the pathobiology of TBI. Such biomarker panels have often been used in research into markers for CNS disorders 31 , and could potentially provide complementary and more-comprehensive information, as well as enabling more-accurate characterization and risk stratification of patients with TBI. A downside of multiplexing rather than focusing on a single analyte, however, is that it can be difficult to optimize the analytical conditions for several antigen-antibody interactions, especially if their concentrations or biochemical characteristics are substantially different.
Technical challenges.
The technical issues associated with ELISA are mainly a question of antibody sensitivity and specificity. In theory, simply extending the duration of the enzyme reaction should increase the sensitivity of the assay; however, the substrates used are inherently unstable and, therefore, produce a weak signal even in the absence of enzyme. This results in a background signal that can mask the signal generated by the sandwich complex, making quantification of the 'true' signal difficult at low substrate concentrations. The ability of the sandwich complex to correctly represent the concentration of the biomarker in a sample strongly depends on the quality of the antibodies used: if the antibodies crossreact with other substances, a signal can be measured even in the absence of the target analyte. The risk of such phenomena is higher in the blood than in the CSF, as blood is much denser in protein content: even minor (for example, 0.1%) crossreactivity against proteins will have a large effect on the measured concentration when the proteins are present at concentrations 1,000,000 times higher than the substrate.
New ultrasensitive technologies provide a number of solutions for the background signal problem. Most of these technologies rely on antibody-based detection of the target molecule, but in Single-Molecule Array (Simoa; Quanterix, Lexington, Massachusetts, USA) the detection reaction is compartmentalized into a small volume (50 fl), so that the reporter molecule accumulates at a very high concentration 32 . In Single-Molecule Counting (Singulex; Alameda, California, USA), the labelled detection antibodies, specifically captured by the target molecule and capture antibody complex, are released and counted one by one in a small detection cell, which enables a single-molecule read-out 33 . In the proximity extension assay (also known as PEA), partly overlapping complementary DNA strands are attached to different antibodies, allowing the strands to form a polymerase chain reaction-amplifiable template if they are immobilized close to each other on the same molecule 34 . These variations in signal generation or detection can make assays 10-1,000-fold more sensitive than the corresponding regular ELISA using the same antibody pair.
When antibody-based assays are used on plasma or serum samples, it is essential to evaluate the assay for potential interference of human anti-mouse antibodies (HAMAs). HAMAs are heterophilic antibodies that can bind mouse (or other species) antibodies and bridge the capture and detection antibodies, thereby replacing the analyte and giving a falsely elevated signal 26 . In humans, the prevalence of such antibodies is about 5% 35 . Several blockers against HAMAs are commercially available, most of which are simply based on the addition of an excess of polyclonal mouse IgG that would sequester any interfering antibodies.
Mass spectrometry
Assays based on mass spectrometry are increasingly important in clinical laboratory medicine, mostly to measure small molecules, such as drugs, amino acids, hormones and vitamins, in an antibody-independent manner 36 . Mass spectrometers are also used in exploratory proteomics studies to identify new biomarker candidates. However, explorative proteomics has so far failed to generate validated TBI biomarkers and, in general, the use of mass spectrometry in standardized quantification of peptides and proteins for routine diagnostic use remains rare 37 . Currently, no established mass spectrometry assays exist for TBI biomarkers, but this situation may well change in the coming years, thanks to rapid technological development.
Fluid biomarkers for acute TBI TBI-associated neuronal, axonal, oligodendrocytic, astroglial and blood-brain barrier injury and neuroinflammation (FIG. 1) are reflected in a number of established and candidate fluid biomarkers. Given that TBI is a condition with a distinct onset, and because of the different phases of pathophysiological responses after TBI 38 , the timing of the biomarker sampling is crucial. If the intended use of the biomarker candidate is to quantify the initial damage, such a biomarker should probably be examined as early as possible, taking biomarker kinetics into account. By constrast, a biomarker for a delayed response, such as neuroinflammation or Wallerian degeneration, can be negative at early time points and reach its maximum concentration days or even weeks to months following the trauma (FIG. 2) . In this section, we give a detailed account of the biomarker candidates for acute TBI that have been examined so far.
Neuronal injury
Neuron-specific enolase. Neuron-specific enolase (NSE) is a glycolytic enzyme that converts 2-phosphoglycerate to phosphoenolpyruvate 39 . The protein shows enrichment in neuronal cell bodies 40 , but is also found in neuro endocrine cells, oligodendrocytes and blood platelets. The main limitation of this marker is that it is present in erythrocytes at particularly high concentrations 39, 41 and, consequently, even invisible haemolysis will contaminate the sample 42 . NSE could be an indicator of poor prognosis: in the hours to days following severe TBI, NSE concentrations in ventricular CSF are higher in nonsurvivors than in survivors. Moreover, the NSE concentration correlates with TBI severity scores in both adults and children [43] [44] [45] [46] [47] . The extent to which these findings depend on release of NSE from injured neurons or lysed erythrocytes is currently unknown, so studies in which NSE concentrations are compared with free haemoglobin levels are needed.
Numerous studies have examined NSE in the serum as a potential biomarker for mild TBI. Initial results were promising, showing increased serum NSE concentrations in samples taken from patients with mild TBI within a few hours post-injury [48] [49] [50] , but when the data were scrutinized, the overlap with nonconcussed controls made the diagnostic utility of this marker uncertain. One study examined the diagnostic performance of serum NSE concentration 3 h after injury to identify intracranial lesions in mild TBI, and found a sensitivity of 56% and a specificity of 77% 51 . A recent study on sports-related concussion also produced disappointing results, with no increase in serum NSE concentrations being detected over hours to days following concussion, compared with preseason concentrations 52 . In summary, serum NSE does not seem to be a sensitive enough blood biomarker for mild TBI.
Ubiquitin C-terminal hydrolase-L1. Another candidate biomarker for TBI is ubiquitin C-terminal hydrolase-L1 (UCHL1), a protein that, like NSE, shows enrichment in the cytoplasm of neurons. UCHL1 is not CNS-specific: it is also expressed in neurons of the PNS 53 , as well as in cells of the neuroendocrine system 54 , endothelial and smooth muscle cells 55 , and some tumours 56 . Nevertheless, increased serum and CSF concentrations of UCHL1 have been reported in patients with severe TBI, the highest concentrations being seen within 24 h after injury in patients with poor outcome 57 . A number of papers have examined serum UCHL1 as a potential biomarker for mild TBI, but the studies were small and the results inconsistent 58 . In one of the larger studies, serum samples were collected within 4 h after injury from 86 patients with mild TBI and 10 patients with moderate TBI, as well as from trauma and nontrauma controls 59 . Serum UCHL1 concentrations were increased in both TBI groups compared with the control groups. Another study reported that serum UCHL1 concentrations in samples obtained within 24 h after injury could distinguish mild TBI patients with intracranial lesions from those without intracranial lesions 60 -a result that calls for additional replication studies.
Brain-derived neurotrophic factor. Brain-derived neuro trophic factor (BDNF) is another protein that is highly expressed in neurons. BDNF is a member of the nerve growth factor family, and activation of intracellular BDNF receptors promotes neural regeneration, reconnection, and dendritic sprouting 61 . One might envisage that neuronal injury in TBI would result in increased fluid concentrations of this potential biomarker, but in a study published in 2016, day-of-injury serum BDNF concentrations were lower in patients with TBI than in controls, with particularly low levels being seen in patients with severe TBI 62 , suggesting that insufficient BDNF release after injury might indicate a poor outcome. However, another recent study performed in plasma did not support an association between BDNF concentration and TBI outcome 63 .
Axonal injury
Tau and neurofilaments. The best-established CSF biomarkers for axonal injury are tau and neuro filament light (NF-L) and neurofilament heavy (NF-H) polypeptides 64 . Tau is a microtubule-associated protein that is abundant in axons, but can also be detected in liver, kidney and testis 65 . Moreover, a larger isoform of tau (called 'big tau'), which contains the epitopes that are used to measure tau with the currently available immuno assays, is expressed in peripheral nerves 66 . NF-L and NF-H are also structural axonal proteins but, in contrast with tau, which is predominantly expressed in thin unmyelinated axons of the cortex 67 , neurofilaments are highly expressed in large-calibre myelinated axons that extend subcortically 68 . NF-L and NF-H are also expressed in peripheral nerves 68 . Phosphorylation of tau is a normal event in healthy neurons, but hyperphosphorylation and aggregation into neurofibrillary tangles is a characteristic of AD Nature Reviews | Neurology Myelin basic protein (MBP) is a candidate biomarker for white matter integrity. Neuron-specific enolase (NSE) and ubiquitin C-terminal hydrolase-L1 (UCHL1) are proteins that show enrichment in the neuronal soma, and are putative biomarkers for neuronal injury. In traumatic brain injury, activated astrocytes and microglia secrete S100-B and glial fibrillary acidic protein (GFAP), as well as interleukins, cytokines and matrix metalloproteinases. The cerebrospinal fluid (CSF):serum albumin ratio is an established biomarker for blood-brain and/or blood-CSF barrier integrity. Plasma occludin is a candidate biomarker in the blood for the same function.
and CTE 65 . Both total tau (t-tau) and phosphorylated tau (p-tau) can be measured in the CSF. T-tau is measured with assays that do not discriminate between unphosphorylated and phosphorylated forms of tau, or between tau molecules translated from differently spliced mRNAs, whereas p-tau is measured with sandwich immunoassays in which at least one of the antibodies is specific to a phosphorylated epitope of tau.
T-tau concentrations in the ventricular CSF correlate with lesion size and outcome in severe TBI, with high levels indicating worse injury [69] [70] [71] . By contrast, CSF p-tau concentrations, as measured by currently available p-tau assays, are unchanged in TBI and other forms of acute brain injury 72, 73 . Studies on mild TBI show increased CSF concentrations of both t-tau and NF-L, although the increase in CSF NF-L is greater than the increase in t-tau, suggesting that blows to the head have a greater impact on long, large-calibre axons that extend subcortically than on short, nonmyelinated axons in the cortex 73, 74 . Similar results have been observed for CSF NF-H 75 . Serum tau concentrations have been examined in both paediatric and adult patients with mild TBI and com pared with findings on CT scans of the brain. Com pared with nonconcussed controls, patients with concussion showed increased serum tau concentrations 76, 77 , but no difference was observed between patients with CT signs of brain injury and patients with no such signs 76, 78 . However, in these studies, a regular tau ELISA was used, so the assay was not optimized for the low concentrations of tau in the blood, and the sample diluent did not contain blockers against heterophilic antibodies, making the data uncertain. In moderate and severe TBI that required treatment in a neurointensive care unit, serum NF-L concentrations, as measured by regular ELISA, were increased, but no correlation with diffuse axonal injury or intracranial damage, as assessed by CT, was seen 79 . Standard ELISAs for t-tau and NF-L were recently transferred onto the Simoa platform, which enables ultrasensitive measurement of these proteins in the blood 80, 81 . Plasma t-tau concentration correlates poorly with CSF concentration 82 , but in acute hypoxic brain injury, a biphasic release of tau into the bloodstream was observed, with a first peak occurring during the first few hours after injury, and a second broad peak occurring after a few more days; these increases were predictive of outcome 80 . In a study of concussed professional ice hockey players, plasma t-tau concentrations were increased 1 h after injury compared with preseason concentrations, and predicted return-to-play time (that is, when the player was symptom-free and, therefore, deemed on clinical grounds to be fit to return to play) with high accuracy 52 . In another study of 34 patients with varying degrees of TBI, plasma tau concentrations in samples collected within 24 h after injury showed high accuracy to differentiate patients with complicated mild TBI from controls 83 . Recently, increased mean plasma tau concentrations were reported in military personnel with a history of self-reported TBI compared with controls without such a history 84 . In addition, postconcussive symptoms were found to correlate with plasma tau concentrations in the TBI group, suggesting that the increase, though variable, might be of pathophysiological relevance.
In axonal injury, tau can be proteolytically cleaved by activated caspases and calpains, generating fragments that can be measured in blood. In one study, serum tau fragment concentrations in concussed ice hockey players were variable, but peaked at 12 h after injury, with the highest concentrations being seen in individuals who took longer than 10 days to become asymptomatic 85 . No correlation has been observed between serum tau fragments and postconcussive symptoms 3 months after mild TBI, suggesting that these fragments are not a late marker 86, 87 . Serum NF-L concentrations, measured by Simoa, correlate strongly with CSF NF-L 81, 88 , and were found to increase over the course of a season in American football athletes 89 , which could reflect head impacts, although it should be noted that the changes were minor, and that no direct assessment in relation to concussion has been performed to date. In one study, serum concentrations of NF-H were examined at days 1 and 3 after mild TBI 90 . At both time points, serum NF-H concentrations were increased compared with concentrations in control After traumatic brain injury, blood-brain barrier disruption and axonal disconnection are thought to occur almost instantaneously, probably together with fast astrocytic and microglial activation and induction of a hypermetabolic state that can induce long-term oxidative stress and mitochondrial dysfunction. Microglial activation can linger after the initial injury, and can participate in a delayed response along with other neuroinflammatory processes. Wallerian degeneration can continue for months and even years following the injury, and is signified by breakdown of axonal debris distal to the injury. The optimal time point for biomarker sampling depends on the aspect of the TBI process that the biomarker candidate is thought to reflect, and the optimal sampling time for each candidate biomarker must be carefully evaluated in animal models and in human studies by repeated sampling over time.
CSF:serum albumin ratio
Albumin is produced by the liver, so it has to cross the blood-brain barrier to reach the cerebrospinal fluid (CSF). In healthy humans, the ratio of albumin in CSF versus blood is very small, but if the bloodbrain barrier is compromised, the CSF:serum albumin ratio increases. individuals. Serum NF-H concentrations were higher in patients with intracranial abnormalities, such as contusions or bleedings, detected on CT compared with patients with no abnormal CT findings, and correlated inversely with clinical severity scores 90 . This promising result requires replication.
The contribution of extracerebral sources of tau and neurofilaments to the results described above is currently unknown, and must be carefully examined in future studies. However, plasma concentrations of tau did not increase on participation in an ice hockey game without incident concussions 52 . These results differ from what is seen with S100-B -a Ca 2+ -binding protein that is highly expressed in astrocytes -for example, and they sug gest that expression of tau in the brain is sufficiently enhanced in concussion to make blood data interpretable 52 . Furthermore, the strong correlation of plasma and CSF NF-L concentrations indicates that most plasma NF-L is CNS-derived 81, 88 . αII-Spectrin breakdown products. αII-Spectrin is a protein that is abundant in axons and presynaptic terminals, and αII-spectrin breakdown products (SBDPs) have been described as potential biomarkers for brain injury in rats and humans 91, 92 . In TBI and other forms of acute neuronal injury, the protein is processed into breakdown products by calpain and caspase-3, which are activated in dying neurons. SBDPs have been measured in ventricular CSF from patients with severe TBI, and the concentrations correlated with clinical measures of TBI severity and outcome [93] [94] [95] . In plasma, SBDP concentrations were found to increase within 24 h after severe TBI 96 . Serum SBDP concentrations were also increased in some CT-negative cases of mild TBI 97 . Increased serum concentrations of SBDPs have recently been observed from 1 h to 6 days after sports-related concussion 98 .
Oligodendrocytic injury
Myelin basic protein (MBP) is a major component of the myelin sheath made by oligodendrocytes of the CNS and Schwann cells of the PNS 99 . MBP is found at increased concentrations in the CSF of patients with demyelinating diseases such as multiple sclerosis 100 . Because myelinated axons are thought to be primary targets in diffuse axonal injury, MBP has been suggested as a potential biomarker for TBI. To date, studies evaluating MBP as a biomarker of TBI are scarce.
In one study, MBP concentrations in CSF collected from extraventricular drains in cases of severe paediatric TBI were found to be increased manifold compared with CSF MBP concentrations in lumbar CSF from children evaluated for suspected CNS infection; however, the difference between interstitial fluid MBP and lumbar CSF MBP concentrations is unknown 101 . Furthermore, in paediatric TBI, intracranial haemorrhage was associated with elevated serum MBP con centrations 102 . Finally, increased serum MBP concentrations have been detected in adult TBI patients with secondary brain hypoxia 103 . Data from one study suggest that serum MBP concentration could peak 48-72 h after injury -later than the concentrations of S100-B and NSE 102 . MBP might, therefore, have the greatest potential as a biomarker for oligodendrocytic injury in post-acute mild TBI.
Astroglial injury S100-B has been examined extensively as a serum bio marker for TBI, but studies on CSF S100-B are rare. Amateur boxers have slightly elevated CSF levels of S100-B after a bout, although this change is not as pronounced as for the axonal markers t-tau and NF-L 73 . Similar results have been reported for glial fibrillary acidic protein (GFAP) 73, 74 , an intermediate filament protein that is almost exclusively expressed in astrocytes 40 . CSF GFAP has also been evaluated in the context of severe TBI, and ventricular CSF levels of GFAP might improve outcome prediction models in conjunction with clinical data 95 . Clinically relevant changes in serum concentrations of S100-B and GFAP have been reported to detect radiographically apparent intracranial injury [104] [105] [106] . The data from one of these studies suggested that a slight elevation of GFAP has a higher diagnostic accuracy than S100-B, particularly in patients with extracranial fractures that might increase serum levels of S100-B owing to release of the protein from bone 107 . According to new clinical guidelines for the management of head injury, evaluation of S100-B levels could reduce the number of unnecessary brain CT scans 104 . Nevertheless, the use of S100-B as a biomarker remains controversial: in a large convenience sample of adult trauma patients, serum S100-B levels 4 h after injury did not accurately predict intra cranial lesions confirmed on CT 106 . A recent study of 34 patients with varying severity of TBI showed that plasma GFAP collected during the first day after TBI had excellent accuracy in the differentiation of patients with complicated mild TBI from controls 83 .
Blood-brain barrier function
Experimental and human autopsy studies indicate that blood-brain barrier disruption is common in TBI, and can occur almost instantaneously 108 . Following a head injury, cerebrovascular endothelial cells often incur mechanical deformation, as well as shear stress injury 109 , leading to increased tight junction permeability and leakage of molecules across the blood-brain barrier. Theoretically, these events would lead to increased concentrations of CNS-derived molecules in the blood and of blood-derived molecules in the CSF.
CSF:serum albumin ratio. The best-established clinical fluid biomarker for blood-brain barrier integrity is the CSF:serum albumin ratio 21 . Some researchers caution against describing this measure as a blood-brain barrier integrity test and state that it actually reflects the blood-CSF barrier at the choroid plexus 110 . However, in stroke, for example, which leaves the choroid plexus intact but injures cerebro vascular endothelial cells, the CSF:serum albumin ratio can be increased 111 , suggesting that the CSF:serum albumin ratio is probably a marker of both barriers.
An increased CSF:serum albumin ratio has been reported in patients with severe TBI 112, 113 . By contrast, no such changes have been seen in mild TBI 74, 114 , suggesting that the blood-brain barrier remains largely intact or only opens up transiently, or that the CSF:serum albumin ratio is not a sufficiently sensitive marker of blood-brain barrier injury in mild TBI.
Potential surrogate measures for blood-brain barrier function. Protein components of tight junctions have been hypothesized to serve as plasma biomarkers for blood-brain barrier injury in TBI 115 . One such protein is occludin, a 65 kDa integral membrane protein that contributes to tight junction stabilization at barriers 115 . However, this protein is not specific to the brain, and is also expressed at high levels in testis, kidney, liver and lung 116 , which might explain why increased plasma concentration of occludin has been observed not only in concussed individuals, but also in patients with orthopaedic injury without concussion 117 .
Neuroinflammation
A large number of studies have reported an intrathecal acute phase inflammatory response after severe TBI, which is reflected in the CSF as increased concentrations of proinflammatory proteins such as IL-6, IL-8 and IL-10 (REFS 112, 113, [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] . Whether this increase reflects increased production of cytokines and interleukins within the CNS in response to the trauma, or leakage across a disrupted blood-brain barrier, or both, is unknown. The potential pathophysiological importance of the changes is supported by the association between a proinflammatory biomarker pattern and worse clinical outcome, not only in TBI 119, 128 but also in other brain insults such as subarachnoid haemorrhage 129 . A pilot study used multiplex bead technology to measure a large number of inflammatory proteins in serum from 16 paediatric patients with mild TBI and 20 paediatric patients who were scheduled for outpatient surgery but were otherwise healthy 130 . Increased concentrations of both IL-6 and matrix metalloproteinase 9 had a sensitivity of 81% and a specificity of 94% for diagnosing mild TBI 130 ; however, given the low number of participants included in the study, this result needs replication. More recently, blood concentrations of inflammatory molecules, such as substance P, soluble CD40 ligand and tissue inhibitor of matrix metallo proteinases, have been associated with outcome in patients with TBI 131 .
Energy deficit
Cerebral energy perturbation seems to have a major role in TBI, and might be detectable by use of markers of mitochondrial dysfunction, oxidative stress and meta bolic change. Studies investigating markers for brain energy deficit in mild TBI are scarce, but a well-recognized feature of severe TBI is elevation of brain extracellular lactate concentrations and the lactate:pyruvate ratio, which is associated with unfavour able clinical outcome 132 . A recent pilot study comparing profiles of amino acids and other small molecules in serum samples from moderate to severe TBI patients identified a pattern of changes in the concentrations of nine metabolites, which could distinguish between patients who developed post-TBI cognitive impairment from those who did not 133 . Another pilot study showed 2-7-fold increases in plasma concentrations of the antioxidant enzyme peroxiredoxin 6 h to several days following mild to severe TBI compared with healthy, non-concussed control individuals. How these changes relate to post-TBI changes in the CNS is currently unknown, and the findings await replication.
Exploratory approaches
To identify novel biomarkers for TBI, virtually unbiased discovery approaches have been used, including proteomics, lipidomics, antigen panels to detect autoantibodies, exosome analyses, and microRNA arrays. So far, most studies have been conducted in animal models of TBI; studies using such approaches in human patients with TBI are limited.
Proteomics
In two independent explorative proteomics studies of human samples, serum amyloid A (SAA) protein was identified as a potential blood biomarker for TBI 134, 135 . However, data from animal models suggest that the increase in SAA is caused by TBI-associated upregulation of SAA protein synthesis in the liver rather than the CNS injury per se 136 . Other replicated findings from proteomics studies in TBI are currently lacking.
Antigen panels
Some antigen panel studies suggest that TBI with blood-brain barrier disruption could induce the production of autoantibodies against CNS antigens, which might be of pathophysiological relevance and potentially influence long-term outcome 137 . Pilot studies indicate that repetitive subconcussive head blows can trigger the production of CNS autoantibodies, as seen in American football players 138 .
Exosome shedding
Another hot topic is whether TBI can induce release of exosomes, microvesicles or other microparticles across the blood-brain barrier into the bloodstream. Pilot data indicate that such events could occur in severe TBI 139 but, to the best of our knowledge, data on mild TBI are lacking.
Lipidomics
Finally, lipidomics-derived data suggest that levels of brain-enriched sphingolipids are increased in the plasma of patients with stroke 140 . This finding would be interesting to explore further in TBI.
MicroRNAs
In one study using microRNA (miR) arrays, elevated plasma levels of miR-16 and miR-92a were found in mild TBI, but the results were difficult to interpret because patients with severe TBI had lower levels of these miRs, and the levels in mild TBI were no different from those in patients with orthopaedic injury 141 . One study reported that serum levels of three microRNAs -miR-93, miR-191, and miR-499 -were increased several-fold in patients with TBI up to 21 days (last assessment) 142 ; moreover, the levels of these miRs correlated with TBI severity and outcome, warranting additional validation studies of these potential markers.
Biomarkers in postconcussive syndrome
As discussed above, symptoms of mild TBI usually resolve within days to weeks, but in 15% of patients with concussion, neurological symptoms persist for months or longer 9, 10 . The relationship between repetitive mild TBI and development of PCS -specifically, the relative contributions of neuronal damage and psychogenic or psychosocial mechanisms to the development of long-lasting symptoms -is poorly understood. It is also important to point out that PCS symptoms are not brain-specific, and are often found also in individuals who have not experienced TBI 143 . Standard blood-based biomarkers, such as S100-B, do not detect CNS injury in PCS; however, this could be a sensitivity issue 144 . In a recent pilot study of 16 patients with PCS and 15 matched healthy control individuals, the eight PCS patients whose symptoms had lasted for >1 year had increased CSF concentrations of NF-L, which indicates ongoing axonal injury, and decreased CSF concentrations of the 42-amino-acid form of amyloid-β (Aβ 1-42 ), which could indicate Aβ deposition in the brain parenchyma 145 . These results warrant replication and -if verified -long-term studies to assess whether this biomarker pattern could represent a prodrome of CTE.
Biomarkers in CTE
No established neuroimaging or fluid markers exist for CTE 146 , although the gross morphological changes seen in advanced CTE can be visualized using standard neuroimaging techniques 147 . A number of studies using in vivo markers have attempted to elucidate the molecular pathology of CTE. Five retired players of American football and five matched controls with no history of concussion were PET scanned using FDDNP, a ligand that binds to both neurofibrillary tangles and amyloid aggregates in the brain 148 . Compared with controls, the players showed higher FDDNP signals all subcortical regions and the amygdala -a pattern that is distinct from that seen in AD. Similar results were recently reported in a larger case series 149 . Selective amyloid-PET imaging in TBI has yielded ambiguous data, possibly owing to the diffuse nature of trauma-related amyloid deposits, which are less prone to bind amyloid ligands than are the neuritic plaques seen in AD 150 . No data on fluid markers of tau and Aβ pathology in CTE have been presented so far, although currently available CSF biomarkers for these two pathologies in AD, along with CSF NF-L, can be regarded as promising candidates. Clinical biomarker studies with longitudinal follow-up of patients with chronic or progressive symptoms after TBI are warranted to enable us to learn more about the pathogenesis, risk factors and clinical course of CTE.
Conclusions
The research into biomarkers in mild TBI, PCS and CTE is still in its infancy; a lot of work is required to optimize sample collection (including sampling time points) and storage, to identify and mitigate pre-analytical and analytical confounders, and to optimize the assays to maximize their analytical sensitivity and specificity. Several research consortia are intensively engaged in such work.
Another issue with biomarker research in mild TBI is that there is currently no established reference (or 'gold') standard validated against neuropathology to make the diagnosis. Furthermore, the current imaging methods are not sensitive enough to reliably detect mild TBI. Therefore, we have to rely on clinical criteria for mild TBI as the reference standard for making the diagnosis, which gives us somewhat heterogeneous groups to examine. Although this is an obvious limitation, such clinically diagnosed mild TBI groups could include individuals with varying degrees of biomarker alteration, and longitudinal studies could clarify whether these alterations correlate with the risk of developing PCS or related disorders. Predictive biomarker cut-off points would then have to be independently validated. Similarly, collections of samples from patients with PCS, eventually with autopsy data indicating CTE in some cases, will be useful to find biomarkers that predict CTE. This work will be iterative, requiring extensive collaboration and sharing of materials, methods and samples.
As regards blood-based biomarkers for TBI, promising data exist on the detection of acute and, potentially, delayed effects of TBI, but more replication and validation work needs to be done. Of note, brain pathology in mild TBI can be quite subtle, which puts extra demand on the analytical performance of the employed assays; targeted analyses of key molecules using ultrasensitive technologies are likely to be important in this context. Several important issues regarding the potential clinical usefulness of biomarkers for mild TBI could not be addressed in this Review owing to lack of data. For example, we have not been able to define the optimal analytical platforms (it is simply too early to make such claims), or to discuss the potential of point-of-care testing, turnaround times in the emergency care unit, and similar highly clinically relevant matters. The current state of this research field is that promising biomarker candidates exist, but the findings from individual studies that indicate potential clinical utility await independent replication. Once this requirement has been fulfilled and the clinical context of use for a certain biomarker has been established, the biomarker should be nominated for further standardization work, including the development of certified reference materials and methods to allow proper assay standardization, quality control and cut-off point determination, and to optimize the technical aspects of the analytical methods to enable rapid and cost-effective testing.
